Compare Johnson & Johnson (JNJ) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs PubMatic Inc — how do they compare? Johnson & Johnson trades at $261.04 (market cap $618.09B), while PubMatic Inc trades at $18.77 (market cap $850.88M). The key difference: Johnson & Johnson is far larger — about 726.4× PubMatic Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and PubMatic Inc for 40 Days on average.
| JNJ | PUBM | |
|---|---|---|
Market Cap | $618.09B | $850.88M |
Volume | 6,050,983 | 997,698 |
Sector | Health | Technology |
52-Week High | $278.43 | $19.18 |
52-Week Low | $186.00 | $6.28 |
Typical Hold Time | 129 Days | 40 Days |
Enterprise Value | $646.37B | $754.01M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
PubMatic (PUBM) trades at $19.02, up 2.42% with a bullish technical signal and strong analyst consensus. The company shows mixed fundamentals with negative net income margins but positive cash flow and recent earnings beats. Recent Q2 2026 results exceeded expectations with 11% revenue growth, driven by mobile app and CTV segments. Technical indicators show bullish moving averages with neutral oscillators, while support sits at $18 and resistance at $19.
The outlook remains cautiously optimistic with 64.7% analyst buy ratings and a $19.89 price target. Key opportunities include AI-driven ad growth and market share gains, while risks involve persistent profitability challenges and competitive pressures in digital advertising. The CFO's planned retirement adds transitional uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
